671 related articles for article (PubMed ID: 22491770)
61. Carcinogenic HPV infection in the cervical squamo-columnar junction.
Mirkovic J; Howitt BE; Roncarati P; Demoulin S; Suarez-Carmona M; Hubert P; McKeon FD; Xian W; Li A; Delvenne P; Crum CP; Herfs M
J Pathol; 2015 Jul; 236(3):265-71. PubMed ID: 25782708
[TBL] [Abstract][Full Text] [Related]
62. Targeting Persistent Human Papillomavirus Infection.
Shanmugasundaram S; You J
Viruses; 2017 Aug; 9(8):. PubMed ID: 28820433
[TBL] [Abstract][Full Text] [Related]
63. Vaccines for preventing HPV-related anogenital infection and neoplasia.
Ferris DG
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
[TBL] [Abstract][Full Text] [Related]
64. Control of interferon signaling in human papillomavirus infection.
Koromilas AE; Li S; Matlashewski G
Cytokine Growth Factor Rev; 2001; 12(2-3):157-70. PubMed ID: 11325599
[TBL] [Abstract][Full Text] [Related]
65. Regulation of cell cycles is of key importance in human papillomavirus (HPV)-associated cervical carcinogenesis.
Brenna SM; Syrjänen KJ
Sao Paulo Med J; 2003 May; 121(3):128-32. PubMed ID: 12920476
[TBL] [Abstract][Full Text] [Related]
66. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
67. Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.
Bossler F; Kuhn BJ; Günther T; Kraemer SJ; Khalkar P; Adrian S; Lohrey C; Holzer A; Shimobayashi M; Dürst M; Mayer A; Rösl F; Grundhoff A; Krijgsveld J; Hoppe-Seyler K; Hoppe-Seyler F
mBio; 2019 Feb; 10(1):. PubMed ID: 30755508
[TBL] [Abstract][Full Text] [Related]
68. Genitoanal human papillomavirus infection and associated neoplasias.
Gross G
Curr Probl Dermatol; 2014; 45():98-122. PubMed ID: 24643181
[TBL] [Abstract][Full Text] [Related]
69. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice.
Wang X; Che Y; Chen B; Zhang Y; Nakagawa M; Wang X
Int Immunopharmacol; 2018 Mar; 56():249-260. PubMed ID: 29414659
[TBL] [Abstract][Full Text] [Related]
70. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
71. Human papillomavirus vaccines.
Breitburd F; Coursaget P
Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
[TBL] [Abstract][Full Text] [Related]
72. Biology and pathological associations of the human papillomaviruses: a review.
Cheah PL; Looi LM
Malays J Pathol; 1998 Jun; 20(1):1-10. PubMed ID: 10879257
[TBL] [Abstract][Full Text] [Related]
73. An overview of human papillomaviruses and current vaccine strategies.
Gnanamony M; Peedicayil A; Abraham P
Indian J Med Microbiol; 2007 Jan; 25(1):10-7. PubMed ID: 17377346
[TBL] [Abstract][Full Text] [Related]
74. Papillomavirus-like particles for serology and vaccine development.
Kirnbauer R
Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
[TBL] [Abstract][Full Text] [Related]
75. Model systems of human papillomavirus-associated disease.
Doorbar J
J Pathol; 2016 Jan; 238(2):166-79. PubMed ID: 26456009
[TBL] [Abstract][Full Text] [Related]
76. Induction of Interferon Kappa in Human Papillomavirus 16 Infection by Transforming Growth Factor Beta-Induced Promoter Demethylation.
Woodby BL; Songock WK; Scott ML; Raikhy G; Bodily JM
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437968
[TBL] [Abstract][Full Text] [Related]
77. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response.
Amador-Molina A; Hernández-Valencia JF; Lamoyi E; Contreras-Paredes A; Lizano M
Viruses; 2013 Oct; 5(11):2624-42. PubMed ID: 24169630
[TBL] [Abstract][Full Text] [Related]
78. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
79. The crossroads: divergent roles of virus-specific CD4
van Bockel D; Kelleher A
Immunol Cell Biol; 2023 Jul; 101(6):525-534. PubMed ID: 37159056
[TBL] [Abstract][Full Text] [Related]
80. ADAR1 function affects HPV replication and is associated to recurrent human papillomavirus-induced dysplasia in HIV coinfected individuals.
Pujantell M; Badia R; Galván-Femenía I; Garcia-Vidal E; de Cid R; Alcalde C; Tarrats A; Piñol M; Garcia F; Chamorro AM; Revollo B; Videla S; Parés D; Corral J; Tural C; Sirera G; Esté JA; Ballana E; Riveira-Muñoz E
Sci Rep; 2019 Dec; 9(1):19848. PubMed ID: 31882741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
